Search filters

List of works by Thomas A. Rasmussen

A Novel Toll-Like Receptor 9 Agonist, MGN1703, Enhances HIV-1 Transcription and NK Cell-Mediated Inhibition of HIV-1-Infected Autologous CD4+ T Cells

scientific article published on 17 February 2016

Activation of latent human immunodeficiency virus by the histone deacetylase inhibitor panobinostat: a pilot study to assess effects on the central nervous system

scientific article

Administration of Panobinostat Is Associated with Increased IL-17A mRNA in the Intestinal Epithelium of HIV-1 Patients

scientific article published on December 2015

Administration of a Toll-like receptor 9 agonist decreases the proviral reservoir in virologically suppressed HIV-infected patients

scientific article

Anti-HIV-1 ADCC Antibodies following Latency Reversal and Treatment Interruption.

scientific article published on 24 May 2017

Between a shock and a hard place: challenges and developments in HIV latency reversal

scientific article published on 29 April 2019

Broad activation of latent HIV-1 in vivo

scientific article published on 08 September 2016

Cancer therapies in HIV cure research

scientific article published on 7 September 2016

Clinical Interventions in HIV Cure Research

article

Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B/2A trial

scientific article

Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation

scientific article published on 31 January 2013

Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial

scientific article (publication date: 2012)

Correction: HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days-Implications for HIV Remission

scientific article published on 25 August 2016

Eliminating the latent HIV reservoir by reactivation strategies: advancing to clinical trials

scientific article published on April 2013

Estimating Initial Viral Levels during Simian Immunodeficiency Virus/Human Immunodeficiency Virus Reactivation from Latency

scientific article published on 8 November 2017

Ethics of ART interruption after stem-cell transplantation

scientific article

Evaluation of cardiovascular biomarkers in HIV-infected patients switching to abacavir or tenofovir based therapy

scientific article

HDAC inhibition induces HIV-1 protein and enables immune-based clearance following latency reversal

scientific article published on 17 August 2017

HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days--Implications for HIV Remission

scientific article published on 2 July 2015

HIV-1 transcriptional activity during frequent longitudinal sampling in aviremic patients on antiretroviral therapy

scientific article

Histone deacetylase inhibitor romidepsin inhibits de novo HIV-1 infections.

scientific article published on 20 April 2015

Histone deacetylase inhibitors for purging HIV-1 from the latent reservoir

scientific article

Impact of Allogeneic Hematopoietic Stem Cell Transplantation on the HIV Reservoir and Immune Response in 3 HIV-Infected Individuals

scientific article published on 24 March 2017

Impact of alemtuzumab on HIV persistence in an HIV-infected individual on antiretroviral therapy with Sezary syndrome.

scientific article published on 16 May 2017

In-vivo administration of histone deacetylase inhibitors does not impair natural killer cell function in HIV+ individuals

scientific article published on 01 March 2019

Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat

scientific article

Interleukin-37 Expression Is Increased in Chronic HIV-1-Infected Individuals and Is Associated with Inflammation and the Size of the Total Viral Reservoir

scientific article

Modeling of Antilatency Treatment in HIV: What Is the Optimal Duration of Antiretroviral Therapy-Free HIV Remission?

scientific article published on 11 October 2017

Modeling of Experimental Data Supports HIV Reactivation from Latency after Treatment Interruption on Average Once Every 5-8 Days

scientific article

No adverse safety or virological changes 2 years following vorinostat in HIV-infected individuals on antiretroviral therapy

scientific article published on 15 March 2017

Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial

scientific article published on 15 September 2014

Patient-reported outcomes in daily clinical practise in HIV outpatient care

scientific article published on 21 February 2018

Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapy

scientific article published on 26 January 2022

Pneumococcal conjugate vaccination in persons with HIV: the effect of highly active antiretroviral therapy

article

Relationship between Measures of HIV Reactivation and Decline of the Latent Reservoir under Latency-Reversing Agents.

scientific article published on 15 February 2017

Reversal of Latency as Part of a Cure for HIV-1.

scientific article published on 11 December 2015

Romidepsin-induced HIV-1 viremia during effective ART contains identical viral sequences with few deleterious mutations

scientific article

Serum procalcitonin in pulmonary tuberculosis

scientific article published on 01 February 2011

Shocking HIV out of hiding: where are we with clinical trials of latency reversing agents?

scientific article published on 11 March 2016

Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus Infection

scientific article published on 9 March 2017

The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo

scientific article published on 17 September 2015

The TLR9 agonist MGN1703 triggers a potent type I interferon response in the sigmoid colon.

scientific article published on 2 August 2017

The effect of antiretroviral intensification with dolutegravir on residual virus replication in HIV-infected individuals: a randomised, placebo-controlled, double-blind trial

The histone deacetylase inhibitor panobinostat lowers biomarkers of cardiovascular risk and inflammation in HIV patients

scientific article

The potential role for romidepsin as a component in early HIV-1 curative efforts

scientific article published on 8 March 2016

Treatment of HIV-Infected Individuals with the Histone Deacetylase Inhibitor Panobinostat Results in Increased Numbers of Regulatory T Cells and Limits Ex Vivo Lipopolysaccharide-Induced Inflammatory Responses

scientific article published in January 2018

Use of population based background rates of disease to assess vaccine safety in childhood and mass immunisation in Denmark: nationwide population based cohort study

scientific article

Paulina is supported by:

About Paulina

Help